mTOR inhibitors are mainly used in colorectal cancer patients with PIK3CA mutations, in combination with chemotherapy or other drugs, in order to improve efficacy and overcome resistance (Fricke et al., 2019). Here, PIK3CA is linked to colorectal cancer.